Gastroenteritis caused by Campylobacter bacilli poses a major public health problem worldwide, and its rate has been increasing (
1,
2). The genus
Campylobacter consists of at least 20 species , among them
Campylobacter jejuni is the major cause of diarrhea in many countries (
3).
These bacteria cause diarrhea as their main symptom, which its intensity varies from mild to voluminous. Patients’ stools may be watery or bloody. Another frequent digestive tract symptom is abdominal pain, but vomiting is uncommon. Fever, headache, asthenia, and anorexia can also be present and may precede diarrhea.
The disease develops 2-3 days after the ingestion of contaminated food and the symptoms usually resolve within a week (
4-
6). Sequelae can occur, including the autoimmune-mediated demyelinating neuropathies such as Guillain-Barre and Miller Fisher syndromes (
7).
Campylobacter infection is a zoonotic disease that can be hyperendemic, linked to outbreaks and sporadic infections. Known risk factors for the disease include ingestion of undercooked poultry and other meats, contaminated food and water or unpasteurized milk and dairy products, direct contact with pets, farm animals, small children, and swimming in lakes and travel abroad. Foods of animal origin, particularly poultry, are significant sources of C. jejuni, especially when eaten raw and undercooked or decontaminated following cooking.
Normally, Stool samples remain positive for several weeks (
8-
10). In some countries such as Norway, Romania, Yugoslavia, Hong Kong, and India,
Campylobacter sp. are the second most common cause of bacterial enteritis (
11-
14). However much remains to be done about the epidemiology of these pathogens. In some developing countries like Iran, because the routine culture and isolation of
Campylobacter sp. require special media and incubation temperature, the reports about this pathogen are limited (
15).
While most cases of enteritis do not require antimicrobial treatment because of their short duration and clinically mild and self-limiting symptoms, antimicrobial treatment is necessary for systemic Campylobacter infections, immunosuppressed patients and severe or prolonged illnesses. Treatment appears to be beneficial if it is administered early enough in the course of the disease.
Macrolides, in particular erythromycin, are the usual drugs of choice. However, for the empiric treatment of adults with suspected bacterial gastroenteritis, the preferred drug typically includes a fluoroquinolone (ciprofloxacin) because of its broad scope of efficacy against almost all enteric bacterial pathogens (
16). However, acquired resistance to macrolides, fluoroquinolones and other most widely used antibiotics gives rise to a challenge in campylobacteriosis control worldwide (
17-
20). In developing countries, various patterns of campylobacter susceptibility to antibiotics were described (
21).